Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Afrocentric InvestmentJSE:ACT 53 3-Year EPS without NRI Growth Rate is -28.80% as of Dec. 2025. GuruFocus rates JSE:ACT with a GF Score™ of 53/100 and a GF Value™ of R2.03 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 507 Healthcare Providers & Services companies, Afrocentric Investment ranks worse than 88.56% on this metric.
During the past 12 months, Afrocentric Investment's average EPS without NRI Growth Rate was -53.40% per year.
During the past 3 years, the average EPS without NRI Growth Rate was -28.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -17.20% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -31.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Afrocentric Investment was 400.80% per year. The lowest was -76.90% per year. And the median was 5.60% per year.
Afrocentric Investment (JSE:ACT) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Afrocentric Investment 3-Year EPS without NRI Growth Rate Related Terms
JSE:ACT vs HCA, THC, DVA: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Care Facilities subindustry, Afrocentric Investment's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Afrocentric Investment 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Afrocentric Investment's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Afrocentric Investment's 3-Year EPS without NRI Growth Rate falls into.
Afrocentric Investment 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -28.80% mean?
Afrocentric Investment (JSE:ACT) has a 3-Year EPS without NRI Growth Rate of -28.80% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Afrocentric Investment and its competitors. According to the industry distribution chart, Afrocentric Investment ranks #449 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 88.6%.
Is Afrocentric Investment's 3-Year EPS without NRI Growth Rate too high?
Afrocentric Investment's current 3-Year EPS without NRI Growth Rate is -28.80%. Based on the distribution chart, Afrocentric Investment ranks #449 out of 507 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Afrocentric Investment has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Afrocentric Investment's 3-Year EPS without NRI Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Afrocentric Investment ranks #449 out of 507 companies for 3-Year EPS without NRI Growth Rate. This places Afrocentric Investment in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.00, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Afrocentric Investment and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Afrocentric Investment's current 3-Year EPS without NRI Growth Rate is -28.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Afrocentric Investment stock overvalued right now?
Based on GuruFocus' analysis, Afrocentric Investment (JSE:ACT) is currently considered Possible Value Trap. The stock's GF Value™ is R2.03, compared to a current price of R0.80 — trading 60.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -28.80%. Afrocentric Investment's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Afrocentric Investment (JSE:ACT), the current 3-Year EPS without NRI Growth Rate is -28.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Afrocentric Investment (JSE:ACT) Overvalued in 2026?
Based on GuruFocus' analysis, Afrocentric Investment stock appears to be undervalued.
The current stock price of R0.80 is trading 60.6% below its estimated GF Value™ of R2.03.
GuruFocus considers Afrocentric Investment to be Possible Value Trap.
Key valuation signals for JSE:ACT:
3-Year EPS without NRI Growth Rate: -28.80%
GF Value™: R2.03 vs. price of R0.80 (60.6% below fair value)
No single metric tells the full story. See the JSE:ACT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Afrocentric Investment Corp Ltd is an investment holding company providing specialised services and products to the public and private healthcare sectors. It focuses on making quality healthcare accessible and affordable to members and beneficiaries, with the principal objective of ensuring the delivery of efficient health management services and the distribution of quality products. Its business segments include Healthcare SA, comprising medical scheme administration and health risk management services; Healthcare Retail, comprising pharmaceutical sales and services; Healthcare Africa, comprising healthcare services outside South Africa in Namibia and Mauritius; and IT-related services predominantly within South Africa. It operates across South Africa, Botswana, Mauritius, and Namibia.
53GF Score
Get the complete analysis for JSE:ACT
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:ACT has been successfully added to your 
